Suppr超能文献

蒽环类药物所致心脏毒性的预防与治疗:一项随机对照试验的系统评价和网状Meta分析

Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials.

作者信息

Li Siyu, Li Wenrui, Cheng Mengfei, Wang Xiaoxiao, Chen Wanyi

机构信息

Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.

出版信息

Cardiooncology. 2025 Jul 10;11(1):66. doi: 10.1186/s40959-025-00360-3.

Abstract

BACKGROUND

Anthracyclines are cornerstone chemotherapeutics, but cardiotoxicity limits their use.

OBJECTIVE

This study aims to evaluate the efficacy of various drugs in preventing and treating anthracycline-induced cardiotoxicity (AIC).

METHODS

We conducted an extensive search across seven databases to identify randomized controlled trials (RCTs) pertinent to the prevention and treatment of AIC with medications. Subsequently, a Bayesian Model-based network meta-analysis was performed in the R 4.4.0.

RESULTS

A total of 128 RCTs involving 10,431 cancer patients treated with anthracyclines and 78 drug regimens were included in this study. The network meta-analysis results showed that, compared with patients who did not receive cardioprotective drugs, those treated with Calcium Dibutyryladenosine Cyclophosphate (Mean Difference [95% Credible Interval], 8.760 [0.5917, 16.92]), Carvedilol (4.024 [0.5372, 7.656]), Carvedilol + Candesartan (7.934 [3.159, 12.91]), Compound Salvia Miltiorrhiza + Levocarnitine (9.087 [0.9160, 17.25]), Dexrazoxane (5.066 [2.589, 7.540]), Dexrazoxane + Cinobufacini (11.61 [4.590, 18.70]), Dexrazoxane + Shenqi Fuzheng (13.05 [4.640, 21.40]), Nicorandil (14.24 [5.122, 23.31]), Qiliqiangxin (11.38 [2.826, 19.91]), and Xinmai Long (6.371 [1.735, 11.02]) experienced less decrease in LVEF after chemotherapy. The SUCRA ranking results indicated that the most effective treatment option for preserving LVEF was Nicorandil (SUCRA 91.76%).

CONCLUSION

Apart from Dexrazoxane, Carvedilol, a β-blocker, also appears to show significant potential in preventing AIC. Furthermore, our results indicate that there is insufficient evidence to support the beneficial effects of statins, Sildenafil, Ivabradine, Levocarnitine, N-acetylcysteine, Glutathione, Coenzyme Q10, Vitamin E, and Vitamin C in preventing LVEF decline and exerting a positive effect on the prevention of AIC.

摘要

背景

蒽环类药物是化疗的基石,但心脏毒性限制了它们的使用。

目的

本研究旨在评估各种药物在预防和治疗蒽环类药物所致心脏毒性(AIC)方面的疗效。

方法

我们在七个数据库中进行了广泛检索,以确定与药物预防和治疗AIC相关的随机对照试验(RCT)。随后,在R 4.4.0中进行了基于贝叶斯模型的网络荟萃分析。

结果

本研究共纳入128项RCT,涉及10431例接受蒽环类药物治疗的癌症患者和78种药物方案。网络荟萃分析结果显示,与未接受心脏保护药物的患者相比,接受磷酸二丁酰环磷腺苷钙(平均差[95%可信区间]为8.760[0.5917,16.92])、卡维地洛(4.024[0.5372,7.656])、卡维地洛+坎地沙坦(7.934[3.159,12.91])、复方丹参+左卡尼汀(9.087[0.9160,17.25])、右丙亚胺(5.066[2.589,7.540])、右丙亚胺+华蟾素(11.61[4.590,18.70])、右丙亚胺+参芪扶正(13.05[4.640,21.40])、尼可地尔(14.24[5.122,23.31])启力强心(11.38[2.826,19.91])和心脉隆(6.371[1.735,11.02])治疗的患者化疗后左室射血分数(LVEF)下降较少。累积排序曲线下面积(SUCRA)排名结果表明,对保留LVEF最有效的治疗选择是尼可地尔(SUCRA 91.76%)。

结论

除右丙亚胺外 β受体阻滞剂卡维地洛在预防AIC方面似乎也显示出显著潜力。此外,我们的结果表明,没有足够的证据支持他汀类药物、西地那非、伊伐布雷定、左卡尼汀、N-乙酰半胱氨酸、谷胱甘肽、辅酶Q10、维生素E和维生素C在预防LVEF下降及对预防AIC发挥积极作用方面的有益效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78e/12243438/66a9051af495/40959_2025_360_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验